These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29222264)

  • 1. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.
    Silverman LB
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):259-264. PubMed ID: 29222264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
    Advani AS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():131-7. PubMed ID: 24319174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
    Kebriaei P; Poon ML
    Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
    Gökbuget N
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in pediatric acute lymphoblastic leukemia.
    Inaba H; Pui CH
    Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
    Rossoff J; Baggott C; Prabhu S; Pacenta H; Phillips CL; Stefanski H; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras N; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Kunicki M; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
    Blood; 2021 Nov; 138(21):2138-2142. PubMed ID: 34499715
    [No Abstract]   [Full Text] [Related]  

  • 13. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
    Curran E; Muffly L; Luskin MR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35503981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
    Fedorov VD; Upadhyay VA; Fathi AT
    Curr Hematol Malig Rep; 2016 Jun; 11(3):165-74. PubMed ID: 26939921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of cellular immunotherapy for childhood leukemia.
    Bonifant CL; Tasian SK
    Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.